Skip to content
Study details
Enrolling now

TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

University of California, Davis
NCT IDNCT03737604ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

200

Study length

about 6.7 years

Ages

18+

Locations

1 site in CA

What this study is about

Researchers are testing whether a continuous infusion of ropivacaine through catheters, or a single dose of liposomal bupivacaine, provides better pain relief after kidney transplantation. The trial will involve adults who have undergone kidney transplants and are experiencing postoperative pain.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Ropivacaine Continuous Infusion Catheter
  • 2.Take Single Dose Liposomal Bupivicaine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

NERVOUS SYSTEM, local anesthetic

Drug routes

infusion

Endpoints

Secondary: Post Operative Care Unit and Hospital Length of Stay, Proportion of pain scores indicating severe pain

Devices

therapeutic

Body systems

Renal